{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029176","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.878649+00:00","generated_at":"2026-06-13T20:04:48.412295+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Crinetics shareholders elect directors, ratify auditor, and approve say-on-pay on annual basis","bullets":["Elected three Class II directors: Caren Deardorf, Weston Nichols (Ph.D.), Stephanie Okey (M.S.) for 3-year terms.","Ratified BDO USA as independent auditor for FY2023 with 48,326,036 votes for, 3,916 against.","Advisory vote on executive compensation approved: 45,092,585 for, 1,192,212 against.","Advisory vote on say-on-pay frequency favored annual votes (41,312,125 for 1-year); company will hold annual votes.","Approximately 90% of outstanding shares (48,336,267) were present at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029176","json":"https://secwatch.observer/filing/0000950170-23-029176.json","markdown":"https://secwatch.observer/filing/0000950170-23-029176.md","text":"https://secwatch.observer/filing/0000950170-23-029176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/0000950170-23-029176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/crnx-20230616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:04:48.412295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30d0fd770de569cf40e0285d7a62ea363a42be52","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, regarding whether the stockholder vote to approve the compensation of the Company's named executive officers should occur every one, two or three years at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, that the compensation of the Company’s named executive officers should occur every one, two or three years. The results of such vote were: Votes For 1 Yr. Votes for 2 Yr. Votes for 3 Yr. Abstentions Broker Non-Votes 41,312,125 1,577 403,696 4,570,396 2,048,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/0000950170-23-029176-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"70aff35d115c56613460c16c9680c9e66ffe6e0b","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 45,092,585 1,192,212 2,997 2,048,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/0000950170-23-029176-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"82c114a8d39144a761625f361818a59e0b6bf62e","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 37,044,248 9,243,546 2,048,473 Weston Nichols, Ph.D. 44,252,003 2,035,791 2,048,473 Stephanie S. Okey, M.S. 36,802,418 9,485,376 2,048,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/0000950170-23-029176-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"c030f122edf02b272131f3b015d4c5a849c1c8ec","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 48,326,036 3,916 6,315 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023029176/0000950170-23-029176-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}